Talin-2 (TLN2)

Homo sapiens — UniProt Q9Y4G6

Gene: TLN2Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

Talin-2 (TLN2) is a protein from Homo sapiens identified by UniProt accession Q9Y4G6, 2542 residues long. MolForge cross-references it against 0 known binders and 168 disease associations.

UniProt accession: Q9Y4G6; gene symbol TLN2.
Organism: Homo sapiens.
Length: 2542 amino acids.
Top disease associations (Open Targets): reticulocyte measurement, reticulocyte count and Immature Reticulocyte Fraction Measurement.
3D structure: AlphaFold model available.

Target properties

Protein name	Talin-2
UniProt accession	Q9Y4G6
Gene	TLN2
Organism	Homo sapiens
Length	2542 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (168)

Diseases linked to this target (Open Targets).

reticulocyte measurement · score 0.48
reticulocyte count · score 0.47
Immature Reticulocyte Fraction Measurement · score 0.43
pulse pressure measurement · score 0.41
heel bone mineral density · score 0.40
glomerular filtration rate · score 0.37
leukocyte count · score 0.36
mean reticulocyte volume · score 0.33
myeloid white cell count · score 0.32
appendicular lean mass · score 0.32

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q9Y4G6-F1	alphafold	PREDICTED	76.00	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y4G6.

Amino-acid sequence (2542 residues)

MVALSLKICV RHCNVVKTMQ FEPSTAVYDA CRVIRERVPE AQTGQASDYG LFLSDEDPRK GIWLEAGRTL DYYMLRNGDI LEYKKKQRPQ KIRMLDGSVK TVMVDDSKTV GELLVTICSR IGITNYEEYS LIQETIEEKK EEGTGTLKKD RTLLRDERKM EKLKAKLHTD DDLNWLDHSR TFREQGVDEN ETLLLRRKFF YSDQNVDSRD PVQLNLLYVQ ARDDILNGSH PVSFEKACEF GGFQAQIQFG PHVEHKHKPG FLDLKEFLPK EYIKQRGAEK RIFQEHKNCG EMSEIEAKVK YVKLARSLRT YGVSFFLVKE KMKGKNKLVP RLLGITKDSV MRVDEKTKEV LQEWPLTTVK RWAASPKSFT LDFGEYQESY YSVQTTEGEQ ISQLIAGYID IILKKKQSKD RFGLEGDEES TMLEESVSPK KSTILQQQFN RTGKAEHGSV ALPAVMRSGS SGPETFNVGS MPSPQQQVMV GQMHRGHMPP LTSAQQALMG TINTSMHAVQ QAQDDLSELD SLPPLGQDMA SRVWVQNKVD ESKHEIHSQV DAITAGTASV VNLTAGDPAD TDYTAVGCAI TTISSNLTEM SKGVKLLAAL MDDEVGSGED LLRAARTLAG AVSDLLKAVQ PTSGEPRQTV LTAAGSIGQA SGDLLRQIGE NETDERFQDV LMSLAKAVAN AAAMLVLKAK NVAQVAEDTV LQNRVIAAAT QCALSTSQLV ACAKVVSPTI SSPVCQEQLI EAGKLVDRSV ENCVRACQAA TTDSELLKQV SAAASVVSQA LHDLLQHVRQ FASRGEPIGR YDQATDTIMC VTESIFSSMG DAGEMVRQAR VLAQATSDLV NAMRSDAEAE IDMENSKKLL AAAKLLADST ARMVEAAKGA AANPENEDQQ QRLREAAEGL RVATNAAAQN AIKKKIVNRL EVAAKQAAAA ATQTIAASQN AAVSNKNPAA QQQLVQSCKA VADHIPQLVQ GVRGSQAQAE DLSAQLALII SSQNFLQPGS KMVSSAKAAV PTVSDQAAAM QLSQCAKNLA TSLAELRTAS QKAHEACGPM EIDSALNTVQ TLKNELQDAK MAAVESQLKP LPGETLEKCA QDLGSTSKAV GSSMAQLLTC AAQGNEHYTG VAARETAQAL KTLAQAARGV AASTTDPAAA HAMLDSARDV MEGSAMLIQE AKQALIAPGD AERQQRLAQV AKAVSHSLNN CVNCLPGQKD VDVALKSIGE SSKKLLVDSL PPSTKPFQEA QSELNQAAAD LNQSAGEVVH ATRGQSGELA AASGKFSDDF DEFLDAGIEM AGQAQTKEDQ IQVIGNLKNI SMASSKLLLA AKSLSVDPGA PNAKNLLAAA ARAVTESINQ LITLCTQQAP GQKECDNALR ELETVKGMLD NPNEPVSDLS YFDCIESVME NSKVLGESMA GISQNAKTGD LPAFGECVGI ASKALCGLTE AAAQAAYLVG ISDPNSQAGH QGLVDPIQFA RANQAIQMAC QNLVDPGSSP SQVLSAATIV AKHTSALCNA CRIASSKTAN PVAKRHFVQS AKEVANSTAN LVKTIKALDG DFSEDNRNKC RIATAPLIEA VENLTAFASN PEFVSIPAQI SSEGSQAQEP ILVSAKTMLE SSSYLIRTAR SLAINPKDPP TWSVLAGHSH TVSDSIKSLI TSIRDKAPGQ RECDYSIDGI NRCIRDIEQA SLAAVSQSLA TRDDISVEAL QEQLTSVVQE IGHLIDPIAT AARGEAAQLG HKVTQLASYF EPLILAAVGV ASKILDHQQQ MTVLDQTKTL AESALQMLYA AKEGGGNPKA QHTHDAITEA AQLMKEAVDD IMVTLNEAAS EVGLVGGMVD AIAEAMSKLD EGTPPEPKGT FVDYQTTVVK YSKAIAVTAQ EMMTKSVTNP EELGGLASQM TSDYGHLAFQ GQMAAATAEP EEIGFQIRTR VQDLGHGCIF LVQKAGALQV CPTDSYTKRE LIECARAVTE KVSLVLSALQ AGNKGTQACI TAATAVSGII ADLDTTIMFA TAGTLNAENS ETFADHRENI LKTAKALVED TKLLVSGAAS TPDKLAQAAQ SSAATITQLA EVVKLGAASL GSDDPETQVV LINAIKDVAK ALSDLISATK GAASKPVDDP SMYQLKGAAK VMVTNVTSLL KTVKAVEDEA TRGTRALEAT IECIKQELTV FQSKDVPEKT SSPEESIRMT KGITMATAKA VAAGNSCRQE DVIATANLSR KAVSDMLTAC KQASFHPDVS DEVRTRALRF GTECTLGYLD LLEHVLVILQ KPTPEFKQQL AAFSKRVAGA VTELIQAAEA MKGTEWVDPE DPTVIAETEL LGAAASIEAA AKKLEQLKPR AKPKQADETL DFEEQILEAA KSIAAATSAL VKSASAAQRE LVAQGKVGSI PANAADDGQW SQGLISAARM VAAATSSLCE AANASVQGHA SEEKLISSAK QVAASTAQLL VACKVKADQD SEAMRRLQAA GNAVKRASDN LVRAAQKAAF GKADDDDVVV KTKFVGGIAQ IIAAQEEMLK KERELEEARK KLAQIRQQQY KFLPTELRED EG

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with TLN2?

The strongest Open Targets associations for TLN2 are reticulocyte measurement, reticulocyte count, Immature Reticulocyte Fraction Measurement, pulse pressure measurement and heel bone mineral density.

How long is the TLN2 protein?

The Homo sapiens TLN2 protein (UniProt Q9Y4G6) is 2542 amino acids long.

Browse: Targets: T · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q9Y4G6 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q9Y4G6 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.